Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Sales

4D Molecular Therapeutics (FDMT) Assets Average (2021 - 2025)

Historic Assets Average for 4D Molecular Therapeutics (FDMT) over the last 5 years, with Q3 2025 value amounting to $448.8 million.

  • 4D Molecular Therapeutics' Assets Average fell 2667.38% to $448.8 million in Q3 2025 from the same period last year, while for Sep 2025 it was $448.8 million, marking a year-over-year decrease of 2667.38%. This contributed to the annual value of $450.1 million for FY2024, which is 4961.27% up from last year.
  • 4D Molecular Therapeutics' Assets Average amounted to $448.8 million in Q3 2025, which was down 2667.38% from $494.7 million recorded in Q2 2025.
  • In the past 5 years, 4D Molecular Therapeutics' Assets Average registered a high of $625.0 million during Q2 2024, and its lowest value of $247.8 million during Q3 2021.
  • Moreover, its 5-year median value for Assets Average was $339.2 million (2022), whereas its average is $386.7 million.
  • Its Assets Average has fluctuated over the past 5 years, first soared by 10954.75% in 2024, then plummeted by 2667.38% in 2025.
  • Quarter analysis of 5 years shows 4D Molecular Therapeutics' Assets Average stood at $297.1 million in 2021, then decreased by 8.77% to $271.0 million in 2022, then grew by 29.43% to $350.8 million in 2023, then surged by 65.99% to $582.2 million in 2024, then decreased by 22.91% to $448.8 million in 2025.
  • Its last three reported values are $448.8 million in Q3 2025, $494.7 million for Q2 2025, and $538.1 million during Q1 2025.